Barclays’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $86.4M | Buy |
1,078,481
+33,366
| +3% | +$2.75M | 0.02% | 543 |
|
|
2025
Q4 | $89.1M | Sell |
1,045,115
-246,310
| -19% | -$20.2M | 0.02% | 545 |
|
|
2025
Q3 | $100M | Buy |
1,291,425
+95,374
| +8% | +$7.45M | 0.02% | 496 |
|
|
2025
Q2 | $93.5M | Buy |
1,196,051
+7,638
| +0.6% | +$570K | 0.02% | 494 |
|
|
2025
Q1 | $86.1M | Sell |
1,188,413
-5,372
| -0.4% | -$384K | 0.02% | 471 |
|
|
2024
Q4 | $88.4M | Sell |
1,193,785
-389,164
| -25% | -$27.2M | 0.02% | 443 |
|
|
2024
Q3 | $104M | Buy |
1,582,949
+488,837
| +45% | +$35.5M | 0.03% | 423 |
|
|
2024
Q2 | $101M | Sell |
1,094,112
-222,400
| -17% | -$19.7M | 0.03% | 387 |
|
|
2024
Q1 | $126M | Buy |
1,316,512
+18,523
| +1% | +$1.56M | 0.04% | 327 |
|
|
2023
Q4 | $99M | Buy |
1,297,989
+179,398
| +16% | +$12.5M | 0.04% | 418 |
|
|
2023
Q3 | $77.5M | Sell |
1,118,591
-81,462
| -7% | -$6.55M | 0.05% | 373 |
|
|
2023
Q2 | $113M | Buy |
1,200,053
+693,374
| +137% | +$60.3M | 0.07% | 246 |
|
|
2023
Q1 | $41.9M | Sell |
506,679
-419,061
| -45% | -$32.9M | 0.02% | 533 |
|
|
2022
Q4 | $69.1M | Buy |
925,740
+122,365
| +15% | +$9.43M | 0.03% | 359 |
|
|
2022
Q3 | $66.4M | Buy |
803,375
+145,855
| +22% | +$14M | 0.07% | 238 |
|
|
2022
Q2 | $62.5M | Sell |
657,520
-368,352
| -36% | -$38.1M | 0.04% | 329 |
|
|
2022
Q1 | $121M | Sell |
1,025,872
-915,514
| -47% | -$103M | 0.09% | 206 |
|
|
2021
Q4 | $252M | Buy |
1,941,386
+560,331
| +41% | +$65.4M | 0.09% | 174 |
|
|
2021
Q3 | $156M | Buy |
1,381,055
+436,022
| +46% | +$49.8M | 0.07% | 226 |
|
|
2021
Q2 | $97.9M | Buy |
945,033
+216,339
| +30% | +$20.4M | 0.05% | 301 |
|
|
2021
Q1 | $60.9M | Sell |
728,694
-119,674
| -14% | -$10.1M | 0.03% | 388 |
|
|
2020
Q4 | $77.4M | Buy |
848,368
+33,927
| +4% | +$2.81M | 0.04% | 317 |
|
|
2020
Q3 | $65M | Buy |
814,441
+312,313
| +62% | +$24.4M | 0.04% | 330 |
|
|
2020
Q2 | $34.7M | Sell |
502,128
-393,738
| -44% | -$28M | 0.03% | 432 |
|
|
2020
Q1 | $56.3M | Sell |
895,866
-132,873
| -13% | -$9.58M | 0.04% | 283 |
|
|
2019
Q4 | $80M | Sell |
1,028,739
-468,924
| -31% | -$36.6M | 0.04% | 328 |
|
|
2019
Q3 | $110M | Sell |
1,497,663
-930,081
| -38% | -$65.3M | 0.07% | 227 |
|
|
2019
Q2 | $149M | Buy |
2,427,744
+868,389
| +56% | +$52.5M | 0.09% | 181 |
|
|
2019
Q1 | $99.5M | Buy |
1,559,355
+251,517
| +19% | +$14.4M | 0.07% | 234 |
|
|
2018
Q4 | $66.8M | Buy |
1,307,838
+375,987
| +40% | +$19M | 0.05% | 283 |
|
|
2018
Q3 | $54.1M | Buy |
931,851
+257,001
| +38% | +$12.6M | 0.04% | 380 |
|
|
2018
Q2 | $32.7M | Sell |
674,850
-238,665
| -26% | -$11.1M | 0.03% | 543 |
|
|
2018
Q1 | $42.5M | Buy |
913,515
+26,304
| +3% | +$1.14M | 0.03% | 485 |
|
|
2017
Q4 | $33.3M | Buy |
887,211
+478,662
| +117% | +$17.6M | 0.03% | 564 |
|
|
2017
Q3 | $14.9M | Buy |
408,549
+96,549
| +31% | +$3.68M | 0.02% | 810 |
|
|
2017
Q2 | $12.3M | Sell |
312,000
-130,980
| -30% | -$4.78M | 0.01% | 850 |
|
|
2017
Q1 | $13.9M | Buy |
442,980
+155,409
| +54% | +$4.87M | 0.02% | 697 |
|
|
2016
Q4 | $8.98M | Buy |
287,571
+175,266
| +156% | +$5.68M | 0.01% | 1008 |
|
|
2016
Q3 | $4.51M | Sell |
112,305
-284,634
| -72% | -$10.7M | 0.01% | 1386 |
|
|
2016
Q2 | $13.2M | Buy |
396,939
+155,901
| +65% | +$5.33M | 0.02% | 704 |
|
|
2016
Q1 | $7.07M | Sell |
241,038
-199,326
| -45% | -$5.5M | 0.01% | 946 |
|
|
2015
Q4 | $11.4M | Buy |
440,364
+64,830
| +17% | +$1.68M | 0.01% | 820 |
|
|
2015
Q3 | $8.89M | Buy |
375,534
+74,526
| +25% | +$1.8M | 0.01% | 1010 |
|
|
2015
Q2 | $7.12M | Sell |
301,008
-660,420
| -69% | -$14.9M | 0.01% | 1246 |
|
|
2015
Q1 | $22.8M | Buy |
961,428
+553,368
| +136% | +$12.4M | 0.03% | 617 |
|
|
2014
Q4 | $8.64M | Buy |
408,060
+62,088
| +18% | +$1.25M | 0.01% | 1290 |
|
|
2014
Q3 | $5.88M | Sell |
345,972
-351,558
| -50% | -$5.55M | 0.01% | 1631 |
|
|
2014
Q2 | $9.88M | Buy |
697,530
+155,736
| +29% | +$2.11M | 0.01% | 1168 |
|
|
2014
Q1 | $6.68M | Buy |
541,794
+6,774
| +1% | +$78.2K | 0.01% | 1489 |
|
|
2013
Q4 | $5.79M | Sell |
535,020
-19,050
| -3% | -$215K | 0.01% | 1699 |
|
|
2013
Q3 | $6.37M | Sell |
554,070
-216,660
| -28% | -$2.53M | 0.01% | 1488 |
|
|
2013
Q2 | $8.63M | Buy |
+770,730
| New | +$9.12M | 0.01% | 1184 |
|
Other funds holding EW
VCM
VPM
Barclays's EW Position: Q1 2026 in Review
Barclays increased its Edwards Lifesciences (EW) stake by 3.2% in Q1 2026, buying an estimated $2.75M and bringing the position to 1,078,481 shares worth $86.4M. The position accounts for 0.02% of the portfolio, ranked #543.
Barclays first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $252M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Barclays held 1,078,481 shares of Edwards Lifesciences worth $86.4M as of Q1 2026.
- Barclays bought 33,366 Edwards Lifesciences shares in Q1 2026, an estimated $2.75M.
- Edwards Lifesciences made up 0.02% of Barclays's portfolio in Q1 2026, its #543 holding.
- Barclays first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- Barclays's Edwards Lifesciences position peaked at $252M in Q4 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.